CL04177 / Cleara Biotech - LARVOL DELTA

Peptide-based pivoting of p53 to target metastatic breast cancer (AACR 2024) - "One of our lead compounds, CL04177 dissociates p53 from its PML scaffold leading to its a nuclear exclusion and initiation of the transcription-independent mitochondrial apoptosis...Moreover, peptides that release scarring markers from nuclear structures can eliminate aggressive cancers in vitro and, most importantly, in vivo, e.g., in p53-mutated, metastatic TNBC. This ability introduces a conceptually new therapeutic option, especially for types of cancer for which there is a high unmet medical need."

Metastases • Breast Cancer • Hematological Malignancies • Leukemia • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer

Cleara Biotech Raises $2.5 Million in Seed Financing to Advance FOXO4-Therapeutics Pipeline for Treating Cancer and Chronic Diseases (Businesswire) - "CLEARA Biotech B.V....announced that it closed a $2.5 million seed financing round earlier in the year, led by Apollo Health Ventures, with participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund. The proceeds will be used to progress Cleara’s compounds toward clinical development and further build the Company’s developmental pipeline and management team....Cleara has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans....Molecular and cellular understanding of cell scarring’s mechanism of action and how FOXO4 restrains this particular form of the cell guardian p53, both lead compounds potently counter viability of scarred cancer cells in 2D culture and 3D organoids, as well as strongly reduce the metastatic burden and infiltration in mouse in vivo models for metastatic colon cancer and triple-negative breast cancer."

Financing • Breast Cancer • Colon Cancer • Gastrointestinal Cancer • Oncology • Triple Negative Breast Cancer